Edwards Lifesciences Corporation $EW Shares Purchased by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP increased its holdings in Edwards Lifesciences Corporation by 6.7%, owning approximately $231.68 million worth of shares as of the latest quarter.
• Analysts have raised their price targets for Edwards Lifesciences, with Piper Sandler increasing theirs from $83.00 to $90.00 and BTIG Research from neutral to buy with a target of $100.00.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, surpassing expectations, along with a revenue of $1.53 billion, reflecting an 11.9% increase year-over-year.

Dimensional Fund Advisors LP increased its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 6.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,196,992 shares of the medical research company's stock after acquiring an additional 201,784 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.55% of Edwards Lifesciences worth $231,676,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC raised its stake in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Brown Advisory Inc. raised its stake in Edwards Lifesciences by 7.6% during the fourth quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after buying an additional 575,699 shares in the last quarter. Deutsche Bank AG raised its stake in Edwards Lifesciences by 10.4% during the fourth quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock valued at $511,044,000 after buying an additional 652,923 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Edwards Lifesciences by 8.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock valued at $482,621,000 after buying an additional 513,468 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Edwards Lifesciences by 21.8% during the fourth quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after buying an additional 1,165,845 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,584 shares of company stock worth $1,897,762 in the last three months. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.5950 on Friday, reaching $81.7550. 3,076,141 shares of the company were exchanged, compared to its average volume of 4,824,093. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company's 50-day moving average is $77.58 and its two-hundred day moving average is $74.69. The firm has a market cap of $48.00 billion, a price-to-earnings ratio of 11.76, a P/E/G ratio of 3.95 and a beta of 1.08. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the prior year, the firm earned $0.70 EPS. The business's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of several research reports. Morgan Stanley upped their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Wells Fargo & Company upped their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a research note on Thursday, August 7th. The Goldman Sachs Group restated a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Robert W. Baird increased their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Finally, Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.